GlobeImmune, Inc: GlobeImmune Announces Completion of $7.5 Million Private
LOUISVILLE, Colo., Feb. 13, 2014 - GlobeImmune, Inc., today announced that on
February 11, 2014, the company completed a $7.5 million private placement of
convertible notes and warrants. The notes accrue interest and will be settled
in cash or stock under various scenarios. Proceeds from the private placement
are to be used for general corporate purposes. SternAegis Ventures, through
Aegis Capital Corp., acted as the placement agent for the offering.
GlobeImmune is focused on advancing multiple clinical programs in infectious
disease and oncology. Ongoing studies of Tarmogen product candidates include a
Phase 2 trial of GS-4774 for chronic hepatitis B being conducted by Gilead
Sciences, Inc. under the company's license agreement, a Phase 2 trial of
GI-6207 in patients with metastatic medullary thyroid cancer being conducted
at the National Cancer Institute (NCI), and GI-6301 being developed under a
license with Celgene Corporation.
This press release does not constitute an offer to sell or the solicitation of
an offer to buy securities, nor shall there be any sale of these securities in
any jurisdiction in which such offer, solicitation or sale would be unlawful
prior to the registration or qualification under the securities laws of any
GlobeImmune is a biopharmaceutical company focused on developing products for
the treatment of infectious disease and and oncology based on its proprietary
Tarmogen platform. Tarmogens are believed to activate the immune system by
stimulating cellular immunity, known as T cell immunity, in contrast to
traditional vaccines that predominately stimulate antibody production. To
date, Tarmogen product candidates have been generally well tolerated in
clinical trials for multiple disease indications and are efficient to
manufacture. In May 2009, the company entered into a collaboration agreement
with Celgene Corporation focused on the discovery, development and
commercialization of product candidates for the treatment of cancer. In
October 2011, the company entered into a worldwide, strategic collaboration
with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic
hepatitis B infection. For additional information, please visit the company's
website at www.globeimmune.com.
Timothy C. Rodell M.D.
President & Chief Executive Officer
S.A. Noonan Communications, LLC
Lena Evans or Tony Russo, Ph.D.
Russo Partners, LLC
T: 212-845-4262 or 212-845-4251
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf
of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for
the content, accuracy and originality of the information contained therein.
Source: GlobeImmune, Inc via Globenewswire
Press spacebar to pause and continue. Press esc to stop.